NCT05644561 2026-04-17
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Clinical Trials
24 trialsNCT06909253 2026-04-17
MG-ARCADIA
AstraZeneca
Recruiting
NCT06312644 2026-04-16
Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy
Alexion Pharmaceuticals, Inc.
Recruiting
NCT06149559 2026-04-14
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT07247279 2026-04-14
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
AstraZeneca
Recruiting
NCT06055959 2026-04-13
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06414954 2026-04-13
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT06435312 2026-04-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-04-13
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT07217587 2026-04-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07221838 2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Recruiting
NCT07249632 2026-04-09
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06680037 2026-04-07
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT06987539 2026-04-07
THYME
Amgen
Phase 2 Recruiting
NCT06193889 2026-04-06
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT06704269 2026-04-06
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT06744920 2026-04-06
RELIEVE
Novartis
Phase 3 Recruiting
NCT06607627 2026-04-01
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06517758 2026-03-30
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT07501702 2026-03-30
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Not yet recruiting
NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT07246564 2026-03-27
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT05403541 2026-03-25
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT06799247 2026-03-24
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Cartesian Therapeutics
Phase 3 Recruiting